Abstract
OBJECTIVE: To evaluate the effects of low-dose growth hormone (GH) therapy combined with diet restriction on changes in body composition and the consequent change in insulin resistance in newly-diagnosed obese type 2 diabetic patients.
DESIGN: Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n = 9; rhGH, 0.15 IU/kg body weight/week) or placebo (n = 9) for 12 weeks.
SUBJECTS: Eighteen newly-diagnosed obese type 2 diabetic patients (age 42–56 y, body mass index 28.1±2.7 kg/m2).
MEASUREMENTS: Body composition and fat distribution parameters (by bioelectrical impedance analyzer and CT scans), serum IGF-1; serum glucose, insulin and free fatty acid (FFA) during oral glucose tolerance test (OGTT); HbA1c; serum lipid profiles; and glucose disposal rate (GDR) by euglycemic hyperinsulinemic clamp at baseline and after treatment.
RESULTS: The fraction of body weight lost as fat lost was significantly greater (0.98±0.39 vs 0.52±0.32 kg/kg, P<0.05) and visceral fat area was decreased more in the GH-treated group compared to the placebo-treated group (27.9 vs 21.6%, P<0.05). Lean body mass and muscle area were reduced in the placebo-treated group, whereas an increase in both was observed in the GH-treated group. GDR the was significantly increased in only the GH-treated group (4.67±1.05 vs 6.95±0.91 mg/kg/min, P<0.05). The GH-induced increase in GDR was positively correlated with the decrease in the ratio of visceral fat area/muscle area (r = 0.588, P = 0.001). Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA1c were significantly decreased after GH treatment. LDL-cholesterol level was decreased in only the GH-treated group.
CONCLUSION: Low-dose GH treatment combined with dietary restriction resulted not only in a decrease of visceral fat but also in an increase of muscle mass with a consequent improvement of the insulin resistance observed in obese type 2 diabetic patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Skarfors ET, Selinus KI, Lithell HO . Risk factors for developing non-insulin dependent diabetes: a 10 years follow up on men in Uppsala Br Med J 1991 303: 755–760.
Kisselbach AH, Peiris AN . Biology of regional body fat distribution: relationship to non-insulin-depedent diabetes mellitus Diabetes Metab Rev 1989 5: 83–109.
Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S . Contribution of intra-abdominal fat accumulation to the impairement of glucose and lipid metabolism in human obesity Metabolism 1987 36: 54–59.
Defronzo RA . The triumvirate; β-cell, muscle, liver: a collusion responsible for NIDDM Diabetes 1988 37: 667–687.
Daniel PM, Love ER, Pratt OE . Insulin-stimulated entry of glucose into muscle in vivo as a major factor in the regulation of blood glucose J Physiol (Lond) 1975 247: 273–278.
Ferini-Strambi L, Franceschi M, Cattaneo AG, Smirne S, Calori G, Caviezel F . Sleep-related growth hormone secretion in human obesity: effect of dietary treatment Neuroendocrinology 1991 54: 412–4l5.
Nam SY, Lee EJ, Kim KR, Lee HC, Nam MS, Cho JH, Huh KB . Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity Metabolism 1996 45: 594–597.
Abate N . Insulin resistance and obesity: The role of fat distribution pattern Diabetes Care 1996 9: 292–294.
Forbes GB . Weight loss during fasting: implication for the obese Am J Clin Nutr 1970 23: 1212–1217.
Clemmons DR, Snyder DK, Williams R, Underwood LE . Growth hormone administration conserves lean body mass during dietary restriction in obese subjects J Clin Endocrinol Metab 1987 64: 878–883.
Snyder DK, Underwood LE, Clemmons DR . Anabolic effects of growth hormone in obese diet-restricted subjects are dose dependent Am J Clin Nutr 1990 52: 431–437.
Bratusch-Marrain PR, Smith D, Defronzo RA . The effect of growth hormone on glucose metabolism and insulin secretion in man J Clin Endocrinol Metab 1982 55: 973–982.
Rizza RA, Mandarino LJ, Gerich JE . Effects of growth hormone on insulin action in man Diabetes 1982 31: 663–669.
Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R . Insulin resistace in acromegaly: defects in both hepatic and extrahepatic insulin action Am J Physiol 1986 250: E269–E273.
Foss MC, Saad MJA, Paccola GM, Paula FJ, Piccinato CE, Moreira AC . Peripheral glucose metabolism in acromegaly J Clin Endocrinol Metab 1991 72: 1048–1053.
Kim KR, Nam SY, Song YD, Lim SK, Lee HC, Huh KB . Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults Horm Res 1999 51: 78–84.
Byrd-Bredbenner C . Computer nutrient analysis software packages: consideration for selection Nutr Today 1988 23: 3–21.
Ashwell M, Cole TJ, Dixon AK . Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography Br Med J 1985 290: 1692–1694.
Defronzo RA, Tobin JD, Andres R . Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 1979 237: E2l4–E223.
Beauville M, Harant I, Crampes F, Riviere D, Tauber MT, Tauber JP, Garrigues M . Effect of long-term rhGH administration in GH-dependent adults on fat cell epinephrine response Am J Physiol 1992 263: E467–472.
Yang S, Xu X, Bjorntorp P, Eden S . Additive effects of growth hormone and testosterone on lipolysis in adipocytes of hypophysectomized rats J Endocrinol 1995 147: 147–152.
Rosenbaum M, Gertner JM, Leibel RL . Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children J Clin Endocrinol Metab 1989 69: 1274–1281.
Cuneo RC, Salomon F, Wilmshurst P, Byrne C, Wiles CM, Hesp R, Sonksen PH . Cardiovascular effects of growth hormone treatment in growth hormone deficient adults: Stimulation of the renin-aldosterone system Clin Sci 1991 81: 587–592.
Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Isaksson OGP . Treatment of adults with growth hormone (GH) deficiency with recombinant human GH J Clin Endocrinol Metab 1993 76: 809–817.
Despres JP, Lamarche B . Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease Nutr Res Rev 1993 6: 137–159.
Yamashita S, Nakamura T, Shimomra I, Nishida M, Yoshida S, Kotani K, Kameda-Takemuara K, Tokunaga K, Matsuzawa . Insulin resistance and body fat distribution Diabetes care 1996 19: 287–291.
Ferranini E, Barrett EJ, Bevilacqua S, Defronzo R . Effects of fatty acids on glucose production and utilization in man J Clin Invest 1983 72: 1737–1747.
Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA, Ferranini E . Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects Metabolism 1987 36: 502–506.
Despres JP . Abdominal obesity as important component of _insulin-resistance syndrome Nutrition 1993 9: 452–459.
Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Tokunaga K . Pathophysiology and pathogenesis of visceral fat obesity Ann NY Acad Sci 1993 676: 270–278.
Tagliaferri M, Scacchi M, Pincelli AI, Berselli ME, Silvestri P, Montesano A, Ortolani S, Dubini A, Cavagnini F . Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women Int J Obes Relat Metab Disord 1998 22: 836–841.
O'Neal DN, Kalfas A, Dunning PL, Christopher MJ, Sawyer SD, Ward GM, Alford FP . The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis J Clin Endocrinol Metab 1994 79: 975–983.
Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtosson B . Growth hormone treat_ment_of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure J Clin Endocrinol Metab 1997 82: 727–734.
Chong PK, Jung RT, Scrimgeour CM, Rennie MJ, Paterson CR . Energy expenditure and body composition in growth hormone deficient adults on exogenous growth hormone Clin Endocrinol 1994 43: 872–877.
Snel YEM, Doerga ME, Brummer RJM, Zelissen PMJ, Zonderland ML, Koppeschaar HPF . Resting metabolic rate, body composition and related hormonal parameters in growth hormone-deficient adults before and after growth hormone replacement therapy Eur J Endocrinol 1995 133: 445–450.
Drent ML, Wever LD, Ader HJ, Van der Veen EA . Growth hormone administration in addition to a very low caloric diet and an exercise program in obese subjects Eur J Endocrinol 1995 132: 565–572.
Ayling CM, Moreland BH, Zanelli JM, Schulster D . Human growth hormone treatment of hypophysectomized rats increases the proportion of type-I fibers in skeletal muscle J Endocrinol 1989 23: 429–435.
Lund S, Flyvbjerg A, Holman GD, Larsen FS, Pedersen O, Schmitz O . Comparative effects of IGF-1 and insulin on the glucose transporter system in rat muscle Am J Physiol 1994 67: E461–E466.
Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B . Importance of growth hormone for the induction of hepatic low density lipoprotein receptors Proc Natl Acad Sci USA 1992 89: 6983–6987.
Angelin B, Rudling M . Growth hormone and hepatic lipoprotein metabolism Curr Opin Lipidol 1994 5: 160–165.
Acknowledgements
We would like to thank the dieticians for providing their skilled dietary support. We would also like to thank LG Biotech (Seoul, Korea) for providing the placebo/rhGH (Eutropin) preparations
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nam, S., Kim, K., Cha, B. et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes 25, 1101–1107 (2001). https://doi.org/10.1038/sj.ijo.0801636
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801636
Keywords
This article is cited by
-
Probabilistic prediction of segmental body composition in Iranian children and adolescents
BMC Pediatrics (2022)
-
Prevalence and risk factors for type 2 diabetes mellitus with Prader–Willi syndrome: a single center experience
Orphanet Journal of Rare Diseases (2017)
-
The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations
Nature Reviews Endocrinology (2013)
-
Obesity, Growth Hormone and Exercise
Sports Medicine (2013)
-
Associations of insulin-like growth factor binding protein-3 gene polymorphisms with IGF-I activity and lipid parameters in adolescents
International Journal of Obesity (2009)